Biomerieux Deutschland GMBH

Biomerieux Deutschland GMBH is a foreign-owned, for-profit medical technology company headquartered in Nürtingen, Germany, that has been registered in the System for Award Management since August 18, 2003. The company specializes in providing advanced diagnostic and laboratory equipment, reagents, and supplies to support United States military medical operations, primarily focusing on microbiological testing systems and infectious disease diagnostic platforms. As a subsidiary of the global biotechnology firm Biomerieux SA, the company leverages specialized expertise in laboratory automation and pathogen identification technologies to serve the U.S. Department of Defense medical infrastructure, with particular emphasis on supporting facilities throughout the Europe Area of Operation.

Biomerieux Deutschland GMBH has received multiple federal contract awards from the Defense Health Agency and Department of the Army Medical Command totaling over $1.2 million in documented ceiling values across purchase orders and blanket purchase agreement calls since 2021. The company's primary product offerings include VITEK 2 COMPACT and VITEK microbiology identification systems, MALDI-TOF mass spectrometry equipment for rapid bacterial identification, FilmArray Torch infectious disease testing platforms, VC-FILM ARRAY TORCH systems, benchtop immunoanalyzers utilizing ELFA technology, blood culture analyzers, and microbiology ID/AST (identification and antimicrobial susceptibility testing) analyzer systems, along with associated laboratory reagents and consumables. Recent significant awards include a $331,303.46 contract for MALDI-TOF equipment and supplies (awarded May 1, 2025), a $164,970.27 contract for microbiology ID/AST analyzer equipment on a cost-per-test basis extending through September 30, 2029 (awarded May 1, 2025), and a $98,345.78 purchase order for a fully automated blood culture analyzer for Landstuhl Regional Medical Center (awarded September 19, 2025). All contracts have been awarded through full and open competition with no set-aside designations, and deliveries have been directed to military medical facilities in Germany, North Carolina, and other European locations. Subcontractors have not been identified in the award documentation, indicating that Biomerieux Deutschland GMBH has served as the prime contractor on all documented awards.

Biomerieux Deutschland GMBH currently holds two active Blanket Purchase Agreements with the Department of the Army Medical Command. The first BPA, awarded on August 1, 2024, carries a $2,000,000 ceiling value and extends through July 31, 2026, functioning as a single-award indefinite delivery vehicle to procure medical supplies, laboratory items, reagents, diagnostic systems, and related equipment for United States Army medical facilities throughout the Europe Area of Operation. The second BPA, awarded on September 20, 2022, also valued at $2,000,000, had an ultimate completion date of September 19, 2024, and supported the Army Medical Materiel Center-Europe and Landstuhl Regional Medical Center with similar categories of laboratory and diagnostic equipment. Under these BPA vehicles, the company received multiple decentralized task orders and calls between 2021 and 2024, including calls for specific fiscal years and quarterly periods, with individual order values ranging from approximately $6,000 to $220,000. The BPAs have generated documented task order activity totaling approximately $430,000 across eight separate calls issued between January 2023 and February 2024, with orders processed through both centralized and decentralized procurement mechanisms managed by the Army Medical Command and Defense Health Agency. These indefinite delivery vehicles provide the contractual framework through which military medical facilities in Europe can order required laboratory diagnostic capabilities, reagents, and medical supplies on a firm fixed-price basis to maintain operational readiness and patient care capabilities.